PD16-07 DETERMINING OPTIMAL STENT DURATION FOLLOWING URETEROSCOPY: 3 VS 7 DAYS
Charles J. Paul(University of Iowa), Chad R. Tracy, George Ghareeb, Nathan A. Brooks(Eli Lilly (United States))
Cited by 0
Related Papers
Multi-Institution Evaluation of Sequential Gemcitabine and Docetaxel as Rescue Therapy for Nonmuscle Invasive Bladder Cancer
|The Journal of Urology|2019|190
100 years of Bacillus Calmette–Guérin immunotherapy: from cattle to COVID-19
|Nature Reviews Urology|2021|154
Characterization of LY2228820 Dimesylate, a Potent and Selective Inhibitor of p38 MAPK with Antitumor Activity
|Molecular Cancer Therapeutics|2013|121
Emerging Impact of Malnutrition on Surgical Patients: Literature Review and Potential Implications for Cystectomy in Bladder Cancer
|The Journal of Urology|2017|90
Kinetic and structural characterization of caspase-3 and caspase-8 inhibition by a novel class of irreversible inhibitors
|Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics|2010|70